1 / 3

Neda Esmailzadeh On behalf of HIVNAT 152 study team

Prevalence of insulin resistance and metabolic syndrome among HIV-infected children receiving lopinavir/ritonavir (LPV/r)-based antiretroviral therapy. Neda Esmailzadeh On behalf of HIVNAT 152 study team. A 48-week study of a randomized trial comparing the efficacy of

joanne
Download Presentation

Neda Esmailzadeh On behalf of HIVNAT 152 study team

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prevalence of insulin resistance and metabolic syndrome among HIV-infected children receiving lopinavir/ritonavir (LPV/r)-based antiretroviral therapy Neda Esmailzadeh On behalf of HIVNAT 152 study team A 48-week study of a randomized trial comparing the efficacy of low dose (70% of standard dose) versus standard dose LPV/r in HIV infected children on ART

  2. Study designs and Methods • Objectives • Primary - To describe prevalence of insulin resistance (IR) and metabolic syndrome(MS) among HIV-infected Thai children receiving LPV/r • Secondary - To compare IR & MS in low dose versus standard LPV/r • Inclusion criteria: < 18 years old, currently on PI • regimens, HIV RNA viral < 50 copies/ml at screening, BW 25-50 kg • Population: • n = 193 on LPV/r • (Low dose = 97; Standard dose = 96)

  3. Results • Prevalence of IR - 6.2 % (95% CI 2.8-9.7) • -Standard LPV/r dose 5.2%, VS. Low dose 7.2%, p = 0.56 • -No association between LPV/r dosage and HOMA-IR score. • Prevalence of IFG =2.1%, TG>150 = 52.3%, HDL <40 =25.4% • Prevalence of MS - 2.6% (95% CI 0.3-4.9) • -Standard LPV/r dose 2.1%, VS. Low dose 3.1%, p = 0.66 • Patient without insulin resistance = 0/181 (0%) • Patient with insulin resistance = 5/12 (41.7%) • Prevalence of IR and MS is low compared to other studies • - IR prevalence up up to 13% (Beregszaszi M et al, 2011) • - MS up to 6% (De Silva RC. et al, 2006) IR – insulin resistance IFG – impaired fasting glucose MS – metabolic syndrome

More Related